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1. Introduction 
Medullary thyroid carcinoma (MTC) is an uncommon primary thyroid carcinoma 
accounting for as much as 10% of all thyroid malignancies and as much as 14% of thyroid 
cancer-related deaths.[1] It is a neuroendocrine malignancy arising from the C cell or 
parafollicular cell of the thyroid.[2] The sporadic and hereditary forms of MTC account for 
80% and 20% of all cases, respectively.[3] The hereditary form is part of the multiple 
endocrine neoplasia (MEN) syndromes including MEN 2A (MTC, pheochromocytoma, and 
hyperparathyroidism), MEN 2B (MTC, pheochromocytoma, mucosal neuroma, and 
marfanoid habitus), and familial MTC (FMTC).[4] About 40% to 50% of sporadic MTC cases 
present with distant metastasis involving cervical lymph nodes, lungs, liver, and/or bones at 
initial diagnosis.[5] The literature reports other rare metastatic sites including pituitary 
metastasis, [6] choroidal and optic disc metastasis, [7,8] breast metastasis, [9] and skin 
metastasis. [10] 
Certain diagnostic tools such as calcitonin and REarranged during Transfection (RET) proto-
oncogene tests enable the discovery of hereditary MTC cases in the preclinical stage, 
allowing for early surgical interventions and resulting in high cure rates. [5] In contrast to 
hereditary MTC, early detection of sporadic MTC is difficult, making prognosis more 
unfavorable. [11] The initial presentation of a metastatic tumor may be difficult to diagnose 
if the clinician is unaware of the occult primary thyroid cancer. Immunohistochemical 
staining with calcitonin for the metastatic tumor has been used as a diagnostic marker for 
MTC. [12] However, no consensus exists regarding calcitonin expression by metastatic MTC 
tissues. Still calcitonin staining is routinely used to make a differential diagnosis of MTC. 
This poses particular challenges when metastatic MTC occurs without the expression of 
calcitonin. 
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We had encountered a case of sporadic MTC in a 73-year-old man who initially presented 
with two ill-defined pulmonary opacities on chest radiography (CXR). Computed 
tomography (CT) of the chest inadvertently found a thyroid nodule, which led to the 
ultimate diagnosis of primary MTC with pulmonary metastasis. This atypical 
histopathologic presentation of pulmonary metastasis from MTC made diagnosis 
particularly challenging. 
2. Body 
The patient was a 73-year-old man with an unremarkable medical history. He had the initial 
presentation of intermittent anterior chest pain for more than 20 days. The CXR showed two 
ill-defined opacities in the upper lobe and the hilum of the right lung (Figure 1B). Chest CT 
findings highly suggested bronchogenic carcinoma localized in the upper and middle lobes 
of the right lung with extension and encasement to the adjacent hilum and the segmental 
bronchus of right upper lobe (Figure 1A). We discovered lymph node metastases to the right 
anterior mediastinum and subcarinal region and an accidental thyroid nodule over the right 
lobe. Initial pathological examination of a transbronchoscopic lung biopsy favored poorly-
differentiated carcinoma with desmoplastic stroma infiltrated by sheets of cancer cells that 
had hyperchromatic nuclei with no distinct nucleoli (Figure 2A, x40).  
 
Figure 1. (A) chest CT at diagnosis: higly suggested bronchogenic carcinoma (B) chest PA at diagnosis: 
two ill-defined opacities over the right upper lobe and the right hilum of the lung (C) chest PA after 
chemotherapy: partial shrinkage of the tumor opacity. Thyroid aspiration (x100 objective lens) with (D) 
Papanicolau's stain: dispersed cell pattern with nuclear eccentricity and "salt-and-pepper" chromatin (E) 
Riu's stain: plasmacytoid cells with binucleation and basophilic stippling in the cytoplasm (F) positive 
calcitonin stain using liquid-based cytology (LBC) method 
Sonography revealed a calcified heterogenous right thyroid tumor greatest diameter 2.9cm. 
Fine-needle aspiration cytology with Papanicolaou’s stain showed cells arranged in 
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dispersed pattern with nuclear eccentricity and “salt-and-pepper” chromatin (Figure 1D, 
x100). Characteristic plasmacytoid cells with binucleation and basophilic stippling in the 
cytoplasm were also noted in the aspiration cytology with Riu’s stain (Figure 1E, x100). 
MTC was highly suspected because there was a positive immunocytochemical staining for 
calcitonin as detected by liquid-based cytology (LBC) with Ligui-PrepTM (LGM International, 
Fort Lauderdale) (Figure 1F, x100), and because serum calcitonin level was above 950 pg/ml 
(normal range: 0-42 pg/ml) and carcinoembryonic antigen (CEA) level at 259 ng/ml (normal 
range: 0-3 ng/ml).  
After total thyroidectomy, the diagnosis of MTC was confirmed by positive 
immunohistochemical staining for chromogranin-A (Figure 2F, x40), synaptophysin 
(Figure 2G, x40), calcitonin (Figure 2H, x40), and Congo-red stain for amyloid. Because of 
the similarity between the histopathologic patterns of focal vascular invasions in the 
thyroid (Figure 2E, x40) and the lung carcinoma (Figure 2A, x40), MTC metastasis to the 
lung was further diagnosed based on a positive finding of chromogranin-A (Figure 2B, 
x40) and synaptophysin (Figure 2C, x40), though there was no staining of calcitonin 
(Figure 2D, x40). 
 
Figure 2. (x40 objective lens) Lung sections staining with H.E. (A) showing poorly-differentiated cancer 
cells infiltrating in desmoplastic stroma, with strong expressions for chromogranin-A (B) and 
synaptophysin (C), but negative calcitonin (D). Thyroid sections staining with H.E. (E) showing focal 
vascular invasions in the thyroid with poorly-differentiated cancer cell morphology resembling that in the 
lung section, with positive expressions for chromogranin – A (F), synaptophysin (G), and calcitonin (H). 
Because the patient had no family history of MTC and no evidence of pheochromocytoma 
and hyperparathyroidism, he was diagnosed with sporadic MTC. As for the treatment, post-
operation chemotherapy with Gemcitabine was administered to treat pulmonary metastasis 
of the MTC. After total thyroidectomy and one course of gemcitabine, serum CEA and 
calcitonin levels decreased to 135 ng/ml and 766.7 pg/ml, respectively. CXR showed partial 
shrinkage of the tumor opacity (Figure 1C). 
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To our knowledge, this is the first reported case of accidental MTC initially presenting as 
pulmonary metastasis without calcitonin expression in the metastatic lesions. A correct 
diagnosis might have been missed if the thyroid nodule had not been discovered. The 
atypical histopathologic patterns in this MTC case could have led to a misdiagnosis of 
double cancer.  
We presented this case with several issues worth discussing. First, the absence of calcitonin 
expression in the pulmonary metastases in our case did not exclude the possibility of 
primary MTC. Calcitonin has been recognized as a specific and sensitive tumor marker for 
MTC. Although the disparity between tissue and serum calcitonin in patient with medullary 
thyroid carcinoma were reported, [13] the follow-up of patients with MTC before and after 
total thyroidectomy by the measurement of calcitonin is still widely used in clinical 
condition. Calcitonin is a small polypeptide hormone of 32 amino acids that is produced 
almost exclusively by neuroendocrine C cells in the thyroid. [14] However, little was known 
about the calcitonin expression in the metastatic tissue of MTC. Only four of 142 MTC cases 
in a retrospective study were described as “atypical”, characterized by cytomorphologic 
features and positive neuroendocrine markers of chromogranins and synaptophysin. 
Among the four cases, three had very little expression of calcitonin and one had no 
expression of this tumor marker. [15] Previous reports have also postulated that the 
metastatic lesion may lose the ability to express calcitonin, [12] which is consistent with the 
patient in this report who exhibited poorly differentiated cancer cell morphology (Figure 
2A, x40) similar to that seen in the focal vascular invasion of thyroid (Figure 2E, x40). The 
pathological mechanisms of the poorly-differentiated MTC cells without calcitonin 
expression are not well understood. Oncocytic variant of MTC seen in the recurrent tumor 
has been documented in the literature to represent a further step in tumor progression and 
may be indicative of a poor prognosis. [16] But regarding the absence of calcitonin 
expression in the metastatic tissue of MTC, no references have been found. Thus we 
postulated two possible mechanisms for the absence of calcitonin expression in the 
metastatic tissue of medullary thyroid carcinoma: the first one is that the potential for 
metastasis increases as cancer cells lose their ability to secrete calcitonin during 
dedifferentiation, and the second explanation is that the secondary environment (metastatic 
site) may have disabled the cancer cells’ ability to secret calcitonin. Further research will be 
needed to elucidate the exact mechanism.  
Second, the radiographic patterns of pulmonary metastasis from MTC in this patient were 
hard to differentiate from primary lung carcinoma. The patient presented with elevated 
serum CEA level and two ill-defined pulmonary opacities in the right upper lobe and the 
right hilum, which clinically resembled primary lung carcinoma. Pulmonary metastases 
from MTC generally exhibit a macronodular, or “cannonball” appearance with clear-cut 
margins.[17] Reticulonodular perihilar lesions,[17] calcified pulmonary metastases,[18] 
and micronodular patterns[17] have also been reported in the literature. The diverse 
radiographic manifestations of pulmonary MTC metastases pose as a diagnostic challenge 
for clinicians. Because 40% to 50% of sporadic MTC cases are initially discovered through 
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distant metastasis,[5] the clinician may need to test the patient’s serum calcitonin level to 
rule out MTC if a thyroid nodule and a pulmonary lesion coexist. We believe that 
immunohistochemical staining with neuroendocrine markers (chromogranin and 
synaptophysin) are more useful than calcitonin expression for testing transbronchoscopic 
lung biopsy specimens, even if elevated serum CEA may favor the possibility of lung 
(adeno)carcinoma. In addition to calcitonin, CEA can be secreted and released by the 
malignant transformed C cells. Although CEA is not specific for the diagnosis of MTC, as 
its levels can be elevated in several types of tumors, the serum levels of CEA is an 
excellent test for monitoring disease progression once the diagnosis of MTC has been 
confirmed. [14]  
In our case, liquid-based cytology (LBC) was particularly helpful in facilitating 
immunocytochemical staining. Although most MTC can be easily diagnosed based on 
cytomorphologic findings in aspirates with Pap-staining[12,19] or Riu’s stain,[20,21] 
calcitonin staining has been regarded as the gold standard for the definitive diagnosis of 
MTC.[12] LBC allows ancillary tests, including immunocytochemical staining, to be 
conducted on residual cell samples.[22] To our knowledge, this is the first reported case of a 
primary thyroid carcinoma confirmed by LBC. Although cervical smear using LBC 
preparation has been described,[23] the role of LBC in thyroid aspiration cytology has yet to 
be explored. We expect the clinical application of LBC in thyroid fine needle aspiration 
cytology to help in establishing correct preoperative diagnoses. 
The five-year and ten-year survival rates of MTC with distant metastasis have been 
estimated at 60% and 40%, respectively.[24] Cancer staging of MTC at initial diagnosis is 
highly predictive of future mortality in long-term follow-up.[25] Radioactive iodine, 
external beam radiation therapy, and conventional chemotherapy have not resulted in 
satisfactory response in metastatic MTC.[26] Combination chemotherapy regimens used to 
treat metastatic MTC, including doxorubicin, cisplatin, fluorouracil, dacarbazine, 
streptozocin, cyclophosphamide, and vincristine have yielded limited outcomes with tumor 
response rates less than 20%.[27] Gemcitabine, a pyrimidine antimetabolite, has not been 
described in the literature as a treatment for MTC.[27] Based on an in vitro study in which 
gemcitabine inhibited proliferation and neuroendocrine activity of human TT cells derived 
from MTC,[28] we used gemcitabine to treat the pulmonary metastasis of MTC in this 
patient. This is the first case report demonstrating partial response to gemcitabine in a 
patient with pulmonary metastasis of MTC.  
3. Conclusion 
In conclusion, metastatic medullary thyroid carcinoma with atypical chest radiography and 
calcitonin-free histopathlogic lung lesions can be difficult to diagnose. This unique case 
report demonstrates that MTC metastatic lesions may not express its routine biomarker, 
calcitonin. 
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